Navigation Links
VIA Pharmaceuticals' Lead Compound, VIA-2291, Chosen as a Top Ten Most Licensable Cardiovascular Program for Windhover Information's Therapeutic Area Partnerships Conference
Date:10/19/2007

O, which is a key enzyme in the biosynthesis of leukotrienes (important mediators of inflammation involved in the development and progression of atherosclerosis). VIA-2291 is being developed as a once-daily, oral drug to target inflammation in the blood vessel wall, thereby potentially decreasing the risk of major adverse cardiovascular events (MACE), including heart attack and stroke. According to the American Heart Association, 15.8 million patients in the U.S. have coronary artery disease.

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease. VIA is building a pipeline of small-molecule drugs that target a significant unmet medical need: reducing inflammation in the blood vessel wall, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. The company's lead drug candidate, VIA-2291, is in multiple Phase II clinical studies in patients with cardiovascular disease. For more information, visit: http://www.viapharmaceuticals.com.

Forward-Looking Statements

This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or to VIA's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause VIA's actual results, levels of activity, performance or achievements to be expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue" or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking statements
'/>"/>

SOURCE VIA Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Quintessence cancer treatment chosen for clinical studies
4. Evansville site chosen for biodiesel plant
5. Fiservs Banklink chosen by Union Bank of California
6. Detection of mRNAs on Cryosections of the Cardiovascular System Using DIG-Labeled RNA Probes
7. Multiplexed Quantitative Peptide Assays for Protein Biomarkers of Cardiovascular Disease in Human Plasma
8. NY Medical Center Selects Camtronics for Cardiovascular Image and Information Management
9. 7 Programming
10. 7 Programming
11. 7 Programming
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... MESA, Calif. , July 24, 2014  Now ... close to home. Rehealth Regenerative Therapies , located ... athletes and other physically active people a new health ... Regardless of age, countless patients suffer from ... sport activities, such as muscle tears, torn rotator cuff, ...
(Date:7/24/2014)... MENLO PARK, Calif. , July 24, 2014 ... biotechnology company in the emerging field of regenerative ... live webcast of a presentation to investors on ... 1:30 p.m. PDT.  The presentation will include an ... pipeline. To access the webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics ...
(Date:7/24/2014)... , July 24, 2014  ECC West Africa, LLC ... with University College Hospital (UCH) Ibadan Board ... project to finance, design, construct, and operate and maintain ... Nigeria . Under the first of the 4-phase ... documents and funding applications. UCH Ibadan intends to finance ...
(Date:7/24/2014)... sophisticated equipment, trained personnel, and detection dogs to ... attacks. A revolutionary new electronic chip with nano-sized ... much easier. , The groundbreaking nanotechnology-inspired sensor, devised ... ,s School of Chemistry and Center for Nanoscience ... Tracense, picks up the scent of explosives molecules ...
Breaking Biology Technology:Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2Nano-sized chip 'sniffs out' explosives far better than trained dogs 2
... 2008 at 9:30 a.m., SUNRISE, Fla., Aug. 1 ... Leonhardt, Chairman and CEO of,Bioheart, will present a corporate ... the Red Chip Investor Conference at the Marriott,Marquis in ... will be,available via the internet by visiting and registering ...
... Monitoring and ... Diagnostic System, ... ), announced it has entered into a non-binding letter of,intent ... a real-time wireless beat-to-beat, intelligent heart monitor and,diagnostic system, designed ...
... Holdings, a newly-formed,holding company that is the parent ... Diagnostics (CMDx), announced today that George Poste,D.V.M., Ph.D, ... with,the company, serving as Non-Executive Vice Chairman and ... of CMDx. Dr. Poste has,been a Director of ...
Cached Biology Technology:Bioheart, Inc. to Present at Red Chip Investor Conference in New York 2Bioheart, Inc., Announces Letter of Intent to Acquire MEDICALGORITHMICS, Ltd. 2Bioheart, Inc., Announces Letter of Intent to Acquire MEDICALGORITHMICS, Ltd. 3Bioheart, Inc., Announces Letter of Intent to Acquire MEDICALGORITHMICS, Ltd. 4Bioheart, Inc., Announces Letter of Intent to Acquire MEDICALGORITHMICS, Ltd. 5Dr. George Poste Named Non-Executive Vice Chairman of CDX Holdings, Parent of Caris Diagnostics and Caris Molecular Diagnostics 2Dr. George Poste Named Non-Executive Vice Chairman of CDX Holdings, Parent of Caris Diagnostics and Caris Molecular Diagnostics 3
(Date:7/24/2014)... , July 24, 2014 /PRNewswire-iReach/ -- The Geneva Healthcare ... cardiac devices, has cut emergency room wait times by ... Diego (UCSD) Medical Center, according to a recent study ... Emergency Departments are using the suite to access data ... or defibrillators. "Using Geneva,s technology platform we ...
(Date:7/24/2014)... (July 24, 2014) Scientists at The New ... one step closer to creating a viable cell ... own cells. , For the first time, ... lines from skin samples of patients with primary ... accelerated protocol to induce these stem cells into ...
(Date:7/24/2014)... animal species for food or commercial food sale, has ... the decline of many species of primates and other ... than half of the species being consumed are birds, ... not only the meat made available for sale but ... by hunters and brought to villages for consumption, we ...
Breaking Biology News(10 mins):UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 3NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2
... Delhi, IndiaThe Government of India,s Department of Biotechnology (DBT) ... III clinical trial of a rotavirus vaccine developed and ... at the International Symposium on Rotavirus Vaccines for IndiaThe ... excellent safety and efficacy profile. The clinical ...
... China, Australia and Japan today reports having sequenced and annotated ... have a powerful genetic system that repairs genetic defects, and ... than 86 percent of the nearly 27,000 genes of the ... and elsewhere as a symbol of spiritual purity and longevity. ...
... Ohio A study has identified microRNA-155 as a ... with acute myeloid leukemia that has normal-looking chromosomes under ... or CN-AML)., The study was led by researchers at ... G. James Cancer Hospital and Richard J. Solove Research ...
Cached Biology News:Rotavirus vaccine developed in India demonstrates strong efficacy 2Rotavirus vaccine developed in India demonstrates strong efficacy 3Rotavirus vaccine developed in India demonstrates strong efficacy 4Scientists sequence genome of 'sacred lotus,' which likely holds anti-aging secrets 2Scientists sequence genome of 'sacred lotus,' which likely holds anti-aging secrets 3Scientists sequence genome of 'sacred lotus,' which likely holds anti-aging secrets 4Study identifies possible new acute leukemia marker, treatment target 2